Terms: = Kidney tumors AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Clinical Outcome
30 results:
1. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
[TBL] [Abstract] [Full Text] [Related]
2. Minors at risk of von Hippel-Lindau disease: 10 years' experience of predictive genetic testing and follow-up adherence.
Vibert R; Lahlou-Laforêt K; Samadi M; Krivosic V; Blanc T; Amar L; Burnichon N; Abadie C; Richard S; Gimenez-Roqueplo AP
Eur J Hum Genet; 2022 Oct; 30(10):1171-1177. PubMed ID: 35918537
[TBL] [Abstract] [Full Text] [Related]
3. Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells.
Allen A; Gau D; Francoeur P; Sturm J; Wang Y; Martin R; Maranchie J; Duensing A; Kaczorowski A; Duensing S; Wu L; Lotze MT; Koes D; Storkus WJ; Roy P
J Biol Chem; 2020 Nov; 295(46):15636-15649. PubMed ID: 32883810
[TBL] [Abstract] [Full Text] [Related]
4. RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with clinical outcome.
Rooney N; Mason SM; McDonald L; Däbritz JHM; Campbell KJ; Hedley A; Howard S; Athineos D; Nixon C; Clark W; Leach JDG; Sansom OJ; Edwards J; Cameron ER; Blyth K
Cancer Res; 2020 Jun; 80(11):2325-2339. PubMed ID: 32156779
[TBL] [Abstract] [Full Text] [Related]
5. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract] [Full Text] [Related]
6. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Huang Y; Wang J; Jia P; Li X; Pei G; Wang C; Fang X; Zhao Z; Cai Z; Yi X; Wu S; Zhang B
Nat Commun; 2019 Mar; 10(1):1245. PubMed ID: 30886153
[TBL] [Abstract] [Full Text] [Related]
7. SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.
Qi Y; Zhang Y; Peng Z; Wang L; Wang K; Feng D; He J; Zheng J
J Cell Mol Med; 2018 Feb; 22(2):1224-1235. PubMed ID: 29239102
[TBL] [Abstract] [Full Text] [Related]
8. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
[TBL] [Abstract] [Full Text] [Related]
9. Independent association of PD-L1 expression with noninactivated vhl clear cell renal cell carcinoma-A finding with therapeutic potential.
Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
[TBL] [Abstract] [Full Text] [Related]
10. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Genetic Alterations in Renal Cell Carcinomas With Tubulocystic Pattern: Tubulocystic Renal Cell Carcinoma, Tubulocystic Renal Cell Carcinoma With Heterogenous Component and Familial Leiomyomatosis-associated Renal Cell Carcinoma. Clinicopathologic and Molecular Genetic Analysis of 15 Cases.
Ulamec M; Skenderi F; Zhou M; Krušlin B; Martínek P; Grossmann P; Peckova K; Alvarado-Cabrero I; Kalusova K; Kokoskova B; Rotterova P; Hora M; Daum O; Dubova M; Bauleth K; Slouka D; Sperga M; Davidson W; Rychly B; Perez Montiel D; Michal M; Hes O
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):521-30. PubMed ID: 26447894
[TBL] [Abstract] [Full Text] [Related]
12. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Song Y; Huang J; Shan L; Zhang HT
Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
[TBL] [Abstract] [Full Text] [Related]
13. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (vhl) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract] [Full Text] [Related]
14. Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival.
Dagher J; Dugay F; Rioux-Leclercq N; Verhoest G; Oger E; Bensalah K; Cabillic F; Jouan F; Kammerer-Jacquet SF; Fergelot P; Vigneau C; Arlot-Bonnemains Y; Belaud-Rotureau MA
Hum Pathol; 2014 Aug; 45(8):1639-46. PubMed ID: 24856572
[TBL] [Abstract] [Full Text] [Related]
15. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma.
Gatto F; Nookaew I; Nielsen J
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):E866-75. PubMed ID: 24550497
[TBL] [Abstract] [Full Text] [Related]
16. The role of aberrant vhl/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract] [Full Text] [Related]
17. Epigenetic expansion of vhl-HIF signal output drives multiorgan metastasis in renal cancer.
Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
[TBL] [Abstract] [Full Text] [Related]
18. clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract] [Full Text] [Related]
19. Active surveillance of renal masses in von Hippel-Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months.
Zhang J; Pan JH; Dong BJ; Xue W; Liu DM; Huang YR
Fam Cancer; 2012 Jun; 11(2):209-14. PubMed ID: 22203439
[TBL] [Abstract] [Full Text] [Related]
20. Investigation of tumor suppressor genes apart from vhl on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract] [Full Text] [Related]
[Next]
